Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bio Life Tech Venture Capital Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

NeoDiagnostix: Cervical DNA Dtex Pap screening follow-up cervical cancer test will be directly marketed to clinical reference labs in 2006, bypassing the need for FDA approval, CEO Gregory Endress says Sept. 14 during the Bio Life Tech Venture Capital Conference in Baltimore, Md. The firm's test is targeted at the 3.5 mil. abnormal Pap tests recorded each year and is intended to complement existing HPV tests such as Ventana Medical'sInform, Cytyc's ThinPrep and Digene's DNAwithPap. Cervical Dtex is based on fluorescent in situ hybridization (FISH) technology, which the firm will also use in an oral cancer diagnostic by 2007. NeoDiagnostix expects revenues of $5 mil. in 2006...

You may also be interested in...

Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees

Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts